Trial Profile
NeSST2: A multi-stage clinical study to develop a non-invasive Short Synacthen Test (SST) with nasally administered Synacthen and salivary cortisol. The validated non-invasive SST will be used to establish normative data in children and to detect adrenal suppression in asthmatic children.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Tetracosactide (Primary) ; Tetracosactide
- Indications Adrenal insufficiency
- Focus First in man; Pharmacokinetics
- Acronyms NeSST2
- 04 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 04 Sep 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 04 Sep 2023 Status changed from suspended to recruiting.